Of note, nemolizumab, functionally blocking monoclonal antibody (mAb) against IL-31RA, has been shown to improve the skin manifestations of atopic dermatitis in a phase II trial, suggesting the potential of IL-31 as a therapeutic target31. Here, IL31 is linked to atopic eczema.